Claudin18.2 mRNA cancer vaccine

The **Claudin18.2 mRNA cancer vaccine** is an investigational off-the-shelf mRNA therapeutic developed by **Moderna** that encodes the Claudin18.2 protein, a tumor-associated antigen highly expressed in gastrointestinal cancers such as gastric and pancreatic tumors. It functions by stimulating an immune response against Claudin18.2-expressing cancer cells, potentially enhancing T-cell mediated antitumor activity. Moderna is collaborating with CARsgen Therapeutics to evaluate it in combination with CT041 (satricabtagene autoleucel), a Claudin18.2-targeted CAR-T therapy, in preclinical studies and a planned phase 1 clinical trial for advanced gastric, pancreatic, and other digestive system cancers.[1][2]